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nsin–aldosterone‑system 
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Acute kidney injury (AKI) is a severe complication of coronavirus disease (COVID‑19) that negatively 
affects its outcome. Concern had been raised about the potential effect of renin–angiotensin–
aldosterone system (RAAS) blockades on renal outcomes in COVID‑19 patients. However, the 
association between RAAS blockade use and incident AKI in COVID‑19 patients has not been fully 
understood. We investigated the association between RAAS blockade exposure and COVID‑19‑related 
AKI in hospitalized patients through meta‑analysis. Electronic databases were searched up to 24th 
December 2020. Summary estimates of pooled odds ratio (OR) of COVID‑19‑related AKI depending on 
RAAS blockade exposure were obtained through random‑effects model. The random‑effect meta‑
analysis on fourteen studies (17,876 patients) showed that RAAS blockade use was significantly 
associated with increased risk of incident AKI in hospitalized COVID‑19 patients (OR 1.68; 95% 
confidence interval 1.19–2.36). Additional analysis showed that the association of RAAS blockade use 
on COVID‑19‑related AKI remains significant even after stratification by drug class and AKI severity. 
RAAS blockade use is significantly associated with the incident AKI in hospitalized COVID‑19 patients. 
Therefore, careful monitoring of renal complications is recommended for COVID‑19 patients with 
recent RAAS blockade use due to the potential risk of AKI.
Coronavirus disease (COVID-19) is a protean viral illness with a potentially life-threatening course, that has 
caused unforeseen and unprecedented socioeconomic burdens. The clinical course of COVID-19 varies widely 
from asymptomatic infection to deadly severe acute respiratory distress syndrome, multi-organ failures, and 
 death1. To date, around 3.2 M people have died due to severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection worldwide, and almost 20% of the total deaths have occurred in the United States. (https:// 
www. who. int/ emerg encies/ disea ses/ novel- coron avirus- 2019). Despite extensive global efforts to identify potential 
therapeutics for COVID-19  patients2–5, the vast majority have not resulted in clinically meaningful improvement. 
While waiting for the worldwide vaccination and the establishment of herd immunity, and with a limited thera-
peutic armamentarium, a better understanding of the risk factors associated with severe/fatal COVID-19 course 
and meticulous medical attention to mitigate these risk factors are crucial in improving its clinical outcome.
Acute kidney injury (AKI) is one of the most common complications of COVID-19, which has been found 
to be significantly related to poorer clinical outcome and increased risk of mortality in COVID-19  patients6. The 
pathogenesis of AKI in COVID-19 patients is likely multifactorial, including direct injury through viral tropism 
leading to endothelial dysfunction, coagulopathy, and complement activation as well as indirect injury through 
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organ crosstalk, dehydration, and exposure to nephrotoxins while receiving COVID-19  treatment7. Several risk 
factors for COVID-19-induced AKI have been addressed in recent studies including older age, male sex, severity 
of COVID-19, and the levels of ferritin, creatine kinase, and brain natriuretic  peptide8,9. Notably, concern had 
been raised about the use of renin–angiotensin–aldosterone system (RAAS) blockade and its potential risk on 
incident AKI in COVID-19 patients based on its potential effect on the reduction of glomerular filtration rate 
as well as increased susceptibility and severity of COVID-19 by enhancing angiotensin-converting enzyme 2 
(ACE2) which is a functional receptor protein for SARS-CoV-27.
RAAS inhibitors are known to affect ACE2 expression and activity, which can hypothetically increase the 
risk of SARS-CoV2 infection by facilitating viral  entry10. On the other hand, an alternative hypothesis has sug-
gested that RAAS blockade may mitigate viral entry into cells by restoring ACE1/ACE2  imbalance11. Beyond 
these speculative assumptions, several clinical studies have shown no clear association between RAAS inhibitor 
use and the incidence of COVID-19 or  mortality12–15. However, the safety data regarding RAAS blockade use 
on COVID-19-related renal dysfunction are relatively scarce. Several recent studies have shown the potential 
detrimental effects of angiotensin-converting-enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) 
use on the development of AKI in COVID-19  patients16–18, but these studies have limitations due to the small 
number of participants.
ACEIs and ARBs are widely used antihypertensive medications, and their use is most prevalent in the elderly 
and chronic kidney disease patients, who belong to the highest risk groups for the development of COVID-
19-related mortalities and multiorgan failure. Thus, further investigation of the potential association of RAAS 
blockade exposure with the development of AKI in COVID-19 patients is crucial to provide proper guidance 
to healthcare providers in order to prevent unnecessary exposure or discontinuation of RAAS inhibitors in 
COVID-19 patients. Therefore, we conducted a systematic review and meta-analysis of the association between 
RAAS blockade use and AKI development in laboratory-confirmed or clinically diagnosed COVID-19 patients.
Methods
Search strategy and study selection. Published articles reporting incident AKI in COVID-19 patients 
and their use of ACEIs or ARBs from January 1, 2020 to December 24, 2020 were identified by searching Pub-
Med, Embase, Cochrane, and Scopus. A search update was conducted on January 15, 2021. An example search 
strategy used for PubMed was as follows: (COVID-19 OR SARS-CoV-2 OR coronavirus) AND (acute kidney 
injury OR AKI OR renal dysfunction) AND (English[Language]). For inclusion, studies were required to meet 
the following criteria: (1) case–control, retrospective or prospective cohort, or descriptive studies published in 
English; (2) human subjects with laboratory-confirmed or clinically diagnosed COVID-19; and (3) reported 
data on pharmacological RAAS blockade exposure either before or during hospitalization and the incidence of 
AKI. The timing of the initiation of RAAS blockade use relative to the hospitalization date was not specified prior 
to analysis. Review articles, case reports, or case series reporting fewer than 10 patients or non-peer-reviewed 
publications were excluded. Any duplicate data among the included studies were identified by assessing whether 
specific studies were conducted in the same hospitals in overlapping time frames or by contacting investigators 
when deemed appropriate. Study selection and data extraction were conducted by two investigators (S.A.L. and 
R.P.) in tandem, and any discrepancies were resolved via a third reviewer’s (J.H.Y.) mediation. Although this 
study’s protocol was not registered in PROSPERO, no relevant protocols for this topic were found in this data-
base during the writing of this review. Of note, the authors did not seek specific institutional review board or 
ethics committee approval for this study because the study was conducted using publicly available data obtained 
from online databases.
Study quality and primary end points. Study quality was assessed using the Newcastle–Ottawa Scale 
(NOS) for retrospective studies. The NOS scale demonstrated good study quality (7–8) in all selected studies 
(Supplemental Table 1). The primary endpoint was the odds ratio (OR) derived from a 2 × 2 contingency table 
using an outcome variable equal to incident AKI and an exposure variable equal to pharmacological RAAS 
blockade use in COVID-19 patients. The following additional analyses were performed: an analysis of the asso-
ciation between incident AKI and class of RAAS blockade drug (ACEI or ARB) and an analysis of the association 
between RAAS blockade use and incidence of moderate-to-severe AKI.
Data extraction and statistical analysis. The author, type of study, location where the study was per-
formed, date of publication, median/mean age, number of AKI cases, RAAS blockade use, definition of AKI, and 
diagnosis criteria of COVID-19 were extracted from each included study. Meta-analysis was performed using 
the package ‘meta’ and ‘metafor’ of the R-project (version 3.6.0, URL https:// www.R- proje ct. org). The summary 
estimate of the incidence of AKI depending on RAAS blockade exposure is presented as ORs and their 95% 
confidence intervals (CIs). Additional analysis of the incidence of AKI depending on ACEIs/ARB use and AKI 
severity were performed in the same way. The pooled ORs with 95% CIs were calculated using the random-
effects model with the restricted maximum-likelihood estimator assuming high heterogeneity in characteristics 
among the included studies. Between-study heterogeneity was assessed using the  I2 statistic and Cochran’s Q 
test with P < 0.10. Additional univariate meta-regression was performed to find potential covariates affecting 
the association between RAAS blockade use and COVID-19-related AKI which can also be the source of high 
heterogeneity. The meta-regression included clinical factors such as age, sex, region, level of care, underlying 
comorbidities, and sample size. Contour-enhanced funnel plot and Egger’s test were used to detect publication 
bias. We also performed trim-and-fill method to evaluate the effect of missing studies and recalculated pooled 
OR with 95% CIs that included the hypothetical studies if deemed appropriate.
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Results
Study selection. Following the initial database search and screening, 60 full-text articles were assessed for 
eligibility; among them, 44 studies were excluded for specific reasons (Fig. 1). Of the remaining 16 studies, only 
14 (n = 17,876) were included in the main meta-analysis that evaluated the association between RAAS blockade 
use and the incidence of COVID-19-related AKI. Of note, studies by Cheng et al. and Hirsch et al. were excluded 
because of overlapping data. However, in the sub-analysis of the association between RAAS blockade use and 
incident moderate-to-severe AKI, studies by Cheng et al. and Hirsch et al. were included instead of their cor-
responding overlapping studies (Peng et al. and Ng et al.) that did not contain the data of interest.
Study characteristics. Table 1 shows the baseline characteristics of the included studies. Overall, the study 
sample sizes ranged from 23 to 9657, and mean/median ages ranged from 59 to 72 years. All included studies 
were observational studies performed in retrospective (n = 15) and prospective (n = 1) settings on COVID-19 
patients requiring hospitalization. Studies were conducted in USA (n = 5), China (n = 2), France (n = 2), the UK 
(n = 2), South Korea (n = 1), Italy (n = 1), Germany (n = 1), Bahrain (n = 1), and Iran (n = 1). Among these stud-
ies reporting on incident AKI and RAAS blockade use in COVID-19, six studies reported additional RAAS 
blockade data stratified by drug class (ACEI vs. ARB). In addition, four studies reported additional data on 
AKI severity (mild vs. moderate-severe). Therefore, these studies were reviewed separately for further analysis. 
Hirsch et al. was excluded in the additional meta-analysis regarding the incidence of AKI depending on ACEIs/
ARB use due to overlapping data with Ng et al. All studies used the Kidney Disease: Improving Global Outcomes 
(KDIGO) guideline for the definition of AKI. Furthermore, RAAS blockade exposure was determined based on 
the medication history at the time of admission in most studies; however, Cheng et al. and Kolhe et al. defined 
the exposure as drug administration during hospitalization. The criteria for COVID-19 diagnosis were based on 
laboratory confirmation using polymerase chain reaction in 14 studies and laboratory confirmation or clinical 
suspicion of COVID-19 in two studies (Soleimani et al. and Zahid et al.).
Use of RAAS blockade is associated with incident AKI in COVID‑19 patients. The random-effect 
meta-analysis of pooled OR showed that RAAS blockade use was significantly associated with an increased risk 
of incident AKI in COVID-19 patients (OR 1.68; 95% CI 1.19–2.36, P = 0.003) with high heterogeneity (79.65%) 
(Fig. 2). Egger’s test was not significant, indicating no obvious publication bias (Fig. 3). Univariate meta-regres-
sion did not reveal any covariates associated with significant effect size differences (Table 2).
Association of RAAS blockade use with incident AKI remains significant in further analyses 
stratified by drug class and AKI severity in hospitalized COVID‑19 patients. Further sub-anal-
ysis was performed to assess whether ACEIs and ARBs had discriminative association with AKI incidence in 
COVID-19 patients. The random-effect meta-analysis of pooled OR showed that both ACEI use and ARB use 
were significantly associated with an increased risk of COVID-19-related AKI incidence (ACEI: OR 2.32; 95% 
CI 1.16–4.65; P = 0.02; ARB: OR 2.45; 95% CI 1.35–4.44; P = 0.003 (Supplemental Fig. 1A,B). Heterogeneity was 
high in both ACEI and ARB exposure analyses. Potential publication bias was found for the association between 
ACEI use and incident AKI through Egger’s test (Supplemental Fig.  2A). Trim-and-fill analysis implied two 
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Figure 1.  Flow diagram of the study selection.
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3.18 (P = 0.5), substantially weakening the significant association found in the original analysis. No significant 
publication bias was found on the association between ARB use and incidence of COVID-19-related AKI based 
on Egger’s test (Supplemental Fig. 2B). Trim-and-fill analysis did not suggest any missing study.
Next, the association between RAAS blockade use and COVID-19-related AKI was analyzed after stratifica-
tion of AKI by severity. The random-effect meta-analysis of pooled OR showed that the use of RAAS blockade 
was significantly associated with moderate-to-severe AKI compared to no/mild AKIin hospitalized COVID-19 
patients (OR 1.31; 95% CI 1.14–1.50; P < 0.001) (Supplemental Fig. 3A). Low heterogeneity was found. Egger’s test 
on the association between RAAS blockade use and moderate-to-severe AKI was not significant, demonstrating 
no obvious publication bias (Supplemental Fig. 3B). Trim-and-fill analysis showed that the small study publica-
tion bias did not significantly affect the effect size (Adjusted OR 1.32; 95% CI 1.15–1.51, P < 0.001).
Discussion
In this meta-analysis of published retrospective and prospective cohort studies, we observed that the exposure 
to RAAS blockade was associated with a higher risk of incident AKI in patients with laboratory-confirmed or 
clinically diagnosed COVID-19. Further meta-analyses stratified by drug class showed that the use of ARBs is 
associated with COVID-19-related AKI incidence, even though the association between ACEI use and COVID-
19-related AKI is limited due to potential publication bias. The association between RAAS blockade use and inci-
dence of moderate-to-severe AKI compared to those of no/mild AKI in COVID-19 patients remained significant.
ACE2 plays a seminal role in COVID-19 pathogenesis as well as RAAS pathway regulation that are critical to 
kidney  function19. The binding of the coronavirus spike protein to a membrane-bound ACE2 receptor is requi-
site for cell invasion and ultimately for disease  manifestation20,21. ACE2 expression is known to be significantly 
Table 1.  Characteristics of included studies. *Age was expressed as median [minimum–maximum] values. 
# The mean age was re-calculated based on the separately reported mean age of each subgroup (AKI and non-
AKI group). IQR interquartile range, SD standard deviation, RAAS renin–angiotensin–aldosterone system, 
AKI acute kidney injury, KDIGO Kidney Disease: Improving Global Outcomes, NHS National Health Services.
Author Location Study design
Median/mean age 
(IQR/SD) Number of patients
Timing of RAAS 




Chaudhri et al.35 New York, USA Retrospective cohort study 59 ± 18 300 Before admission




Cheng et al.36 Wuhan, China Retrospective cohort study 70 (59–77) 119
During hospitaliza-
tion




Dudoignon et al.16 Paris, France Retrospective cohort study 63 (57–69) 51 Before admission




Hirsch et al.37 New York, USA Retrospective cohort study 64 (52–75) 5449 Before admission




Husain-Syed et al.38 Giessen, Germany Prospective cohort study 60 (37–88)* 23 Before admission




Kolhe et al.39 Derby, UK Retrospective cohort study 72
# 1161 During hospitaliza-tion
Based on modified 
KDIGO criteria 





Lim et al.41 Daegu, South Korea Retrospective cohort study 67 (57–78) 130 Before admission




Louis et al.42 Region Grand Est, France
Retrospective cohort 
study N/A 181 Before admission




Ng et al.43 New York, USA Retrospective cohort study 65
# 9657 Before admission Based on KDIGO criteria
Laboratory confirma-
tion
Pelayo et al.44 Pennsylvania, USA Retrospective cohort study 66 ± 15 223 Before admission
Based on KDIGO 
criteria except 
urine volume-based 




Peng et al.45 Wuhan, China Retrospective cohort study 61 (50–69) 4020 Before admission




Russo et al.46 Genoa, Italy Retrospective cohort study 70 ± 16 777 Before admission




Soleimani et al.18 Tehran, Iran Retrospective cohort study 66 ± 13 254 Before admission
Based on KDIGO 
criteria
Laboratory confir-
mation or clinical 
suspicion
Taher et al.47 Manama, Bahrain Retrospective cohort study 54 ± 14 73 Before admission




Tetlow et al.48 London, UK Retrospective cohort study 68 ± 17 557 Before admission




Zahid et al.9 New York, USA Retrospective cohort study 66 (55–75) 469 Before admission
Based on KDIGO 
criteria
Laboratory confir-
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increased in COVID-19  patients22. These findings have led to a prompt therapeutic attention over whether 
modulation of the ACE2 activity/expression can change the clinical course of COVID-19 and whether the use 
of RAAS blockade will cause any difference in clinical outcome based on its modulating role of ACE2 expres-
sion/activity23. Several meta-analyses so far have shown that RAAS blockade use has no detrimental effect on 
the clinical course of COVID-1924–26, but the clinical evidence regarding the use of RAAS blockade on renal 
complication in COVID-19 is sparse.
RAAS blockade is considered nephroprotective in the long term. However, these medications can nega-
tively affect renal function through their effects on periglomerular hemodynamics, systemic blood pressure, and 
natriuresis, especially in the acute setting of physiological  stress27. Therefore, cessation of RAAS blockade use 
is widely applied in medical practice in the context of AKI. Based on the poorer clinical outcome of COVID-19 
patients with AKI and the direct biological role of RAAS blockade in renal filtration, the potential effect of RAAS 
inhibitors on the incidence of AKI in COVID-19 patients is a very intriguing clinical question. To the best of our 
Summary estimate (random effects model)
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7.57% 4.90 [ 2.64, 9.11]
8.12% 4.72 [ 2.78, 8.01]
5.75% 3.56 [ 1.40, 9.04]
2.35% 2.25 [ 0.32, 15.76]
7.43% 2.16 [ 1.13, 4.10]
7.24% 1.93 [ 0.98, 3.79]
7.70% 1.81 [ 0.99, 3.28]
8.73% 1.75 [ 1.14, 2.67]
10.02% 1.23 [ 1.12, 1.34]
8.74% 1.23 [ 0.80, 1.87]
7.99% 1.04 [ 0.60, 1.81]
4.63% 0.79 [ 0.25, 2.54]
8.84% 0.74 [ 0.50, 1.12]
4.89% 0.62 [ 0.21, 1.88]
100.00% 1.68 [ 1.19, 2.36]
Event Total Event Total
Exposure Control
Weight OR [95% CI]Study
Q=63.88, df=13, p<.01; I-squared=79.65%
Figure 2.  Meta-analysis of odds ratios for incident AKI in hospitalized COVID-19 patients based on exposure 
to RAAS inhibitors. Higher odds ratio indicates a higher risk of AKI in the RAAS blockade exposure group. AKI 



















0.02 0.15 1.00 7.50 54.00
Figure 3.  Contour-enhanced funnel plot. The symmetry of the funnel plot indicated no obvious publication 
bias. Inner white zone indicates P-value > 0.1, gray zone indicates 0.05 < P-value < 0.1, dark gray zone indicates 
0.01 < P-value < 0.05, and outer white zone indicates P-value < 0.01.
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knowledge, this is the first meta-analysis on the association of recent RAAS blockade use with development of 
incident AKI in COVID-19 patients. Our study suggests that more careful clinical attention should be paid to 
COVID-19 patients with recent exposure to RAAS blockade due to their higher risk of AKI.
Even though our meta-analysis showed a significant association between recent RAAS blockade use and the 
incidence of AKI in COVID-19 patients, the effect of RAAS blockade use on the outcome of AKI in COVID-19 
patients remains unclear. The recent randomized controlled trial comparing the clinical impact of continuation 
vs. discontinuation of RAAS blockades in COVID-19 patients found that there was no between-group differ-
ence in the development of acute kidney failure requiring  hemodialysis28. Previous studies on AKI suggested 
continuing RAAS blockade use to prevent AKI to CKD transition based on its vaso-protective effects and mor-
tality  benefit29,30. Hines et al. showed that RAAS blockade exposure during AKI did not interrupt renal recovery 
following  AKI31. The role of RAAS inhibition can be even more substantial in COVID-19-related AKI than AKI 
from other etiologies based on the significance of ACE2 in the pathogenesis of SARS-CoV-2 infection. Although 
ACE2 plays a critical role in SARS-CoV-2 viral entry, several experts have suggested that ACE2 might mediate 
an organo-protective role by negatively regulating the RAAS system, mediating vasodilatory, anti-inflammatory, 
and anti-fibrotic  roles32. This regulatory mechanism of ACE2 is shared by RAAS inhibitors, reducing the risk of 
cardiovascular disease due to hypertension and diabetes. Even though our study showed a significant associa-
tion between RAAS blockade use and incident AKI in COVID-19 patients, this should be carefully interpreted. 
Without strong pathophysiological correlation and clinical data, we should not exacerbate the hypothetical risk 
of RAAS blockade use in COVID-19 patients and its potential effect on incident  AKI33.
Interestingly, our study showed a significant association between ARB use and COVID-19-related AKI inci-
dence whereas the association of ACEI use and incident AKI in COVID-19 patients was uncertain due to 
significant publication bias. Further studies to understand whether there is any potential discriminative effect 
of ARB compared to that of ACEI on COVID-19-related AKI would be recommended based on their different 
site of  action34. In addition, our meta-regression analysis did not reveal any clinical factor that can induce effect 
size differences on the association between RAAS blockade use and AKI incidence in COVID-19 patients. This 
result suggests more direct association between RAAS blockade use and COVID-19-related AKI rather than 
being mediated by other clinical factors like age or underlying comorbidities. Further experimental and clini-
cal studies will be necessary to delineate the potential effect of RAAS blockade use on COVID-19-related AKI.
Our study has several limitations. A limited number of studies remained after the initial screening because 
most published studies regarding incident AKI with SARS-CoV-2 infection lacked specific data on recent RAAS 
blockade usage. Moreover, most included studies are observational retrospective studies and could only provide 
crude odds ratio on AKI incidence according to RAAS blockade exposure. Therefore, this meta-analysis may 
not be used to derive any conclusions regarding the cause-and-effect relationship between RAAS blockade and 
AKI in COVID-19 patients, and may also be affected by recall, selection, and publication bias. Inherent to the 
nature of the meta-analysis, significant heterogeneity was found both via statistical methods  (I2, Q) as well as 
via individual manuscript review. This could have originated from variations in the dosage/timing of RAAS 
blockade use as well as different definitions of COVID-19 diagnosis, even though most of the studies followed 
molecular diagnosis for COVID-19 confirmation. To better understand the origin of substantial heterogeneity 
between studies, we performed univariate meta-regression, which did not show any significant association with 
effect sizes. However, other covariates such as race, the dosage of drugs, or frequency of cardiovascular disease 
could not be included in the meta-regression due to missing values in included studies. Multiple meta-regression 
could not be performed due to multiple missing covariate data among the included studies. Lastly, subgroup 
analyses on each potential confounding factor were limited because most of the studies simply described the 
overall prevalence of each factor in the total study population while no specific data was provided depending on 
the RAAS blockade exposure, which remains a potential weakness of our study.
Table 2.  Univariate meta-regression of possible sources of heterogeneity across the included studies.
Heterogeneity factors Co-efficient (95% CI) P-value
Mean age 1.00 (0.92, 1.10) 0.93
Male (%) 0.99 (0.98, 1.00) 0.15
Location
Asia Reference
USA 0.72 (0.26, 1.94) 0.51
Europe 1.00 (0.42, 2.42) 1.00
Level of care
Intensive care only vs. all hospitalization (reference) 0.85 (0.35, 2.03) 0.71
Hypertension (%) 0.99 (0.97, 1.01) 0.42
Diabetes (%) 0.99 (0.96, 1.01) 0.20
Chronic kidney disease (%) 0.97 (0.90, 1.05) 0.43
Sample size
< 1000 Reference
≥ 1000 0.61 (0.29, 1.29) 0.20
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In conclusion, exposure to RAAS inhibitors appears to be associated with a higher risk of COVID-19-related 
AKI. Because of the reliance of our analysis on observational studies, a causal relationship cannot be ascribed 
to RAAS blockade and AKI in COVID-19 and practice-changing recommendations cannot be made on the 
basis of our data. Nonetheless, our study warrants further randomized controlled studies and meta-analyses on 
the effect of RAAS blockade on kidney outcomes to better define the risk/benefit of RAAS blockade use in AKI 
patients with COVID-19.
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